Agilent Technologies, Inc. (A) Stock Analysis
Is A a good investment?
Agilent Technologies, Inc. (A) has a Plutrex AI rating of 52.0/100 as of October 01, 2026, indicating a Hold consensus. The stock is halal-compliant per AAOIFI standards. Key strength: Profitability moat is industry-best: gross margin 53.7% (+31% vs. peers), operating margin 25.6% (+54% vs. peers), ROE 21.0% (+96% vs. peers) — durable competitive advantages with below-average leverage (D/E 0.50x vs. 0.65x industry). Main concern: Valuation has deteriorated further in 7 days: stock +4.2% ($165.32→$172.31), analyst target unchanged at $174.11, upside collapsed to 1.0%, P/E expanded 32.55x→33.93x, PEG expanded 3.20→3.34 — now 14 days and +12.1% from prior entry zone midpoint of $152 with zero fundamental improvement to justify the premium.
Investment Summary
Agilent Technologies (A) at $172.31 is an exceptional business trading at a deeply problematic valuation. The profitability profile is genuinely elite: gross margin 53.7% (vs. industry 41.0%), operating margin 25.6% (vs. industry 16.6%), net margin 19.5% (vs. industry 11.3%), and ROE 21.0% (vs. industry 10.7%) — all best-in-class within Medical Diagnostics & Research. FCF of $1.436B and $1.758B cash ensure no financing risk. However, the P/E of 33.93x paired with only 8.75% next-year EPS growth yields a PEG of 3.34x — over 3x the fair-value threshold of 1.0x. Analyst consensus target of $174.11 implies a mere 1.0% upside from current price ($172.31→$174.11), offering zero margin of safety. The stock has now risen 12.1% in 14 days ($153.69→$172.31) with no fundamental improvement — the valuation problem has compounded further. News is genuinely positive (89/100 sentiment, analyst upgrades, China recovery, new product launches) but cannot justify paying 3.34x PEG for 8.75% growth. This remains: outstanding business, wrong price.
Key Strengths
- Profitability moat is industry-best: gross margin 53.7% (+31% vs. peers), operating margin 25.6% (+54% vs. peers), ROE 21.0% (+96% vs. peers) — durable competitive advantages with below-average leverage (D/E 0.50x vs. 0.65x industry)
- FCF engine of $1.436B annually with $1.758B cash provides exceptional capital allocation flexibility — funds $0.255/quarter dividend, share buybacks, and the Ignite transformation program without external financing
- Positive catalysts converging: China end-market recovery (per headline 'Agilent Technologies Sees Growth From China, Replacement Cycles and Lab Automation'), new TapeStationDx clinical NGS launch, Gen5 AI Cell Identification Module expanding software TAM, and 14/20 analysts at Buy
Key Concerns
- Valuation has deteriorated further in 7 days: stock +4.2% ($165.32→$172.31), analyst target unchanged at $174.11, upside collapsed to 1.0%, P/E expanded 32.55x→33.93x, PEG expanded 3.20→3.34 — now 14 days and +12.1% from prior entry zone midpoint of $152 with zero fundamental improvement to justify the premium
- Structural growth laggard status unchanged: forward EPS growth 8.75% is 55% below industry average 19.54%; revenue growth 8.1% is 48% below industry 15.6%; 5-year CAGR 10.16% is 22% below peers — the market has not yet fully repriced this growth deficit into the P/E, creating ongoing re-rating downside risk
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
Profitability (Score 93/100): Gross margin 53.7% vs. industry 41.0% (+31% premium) — exceptional pricing power. Operating margin 25.6% vs. industry 16.6% (+54% premium) — industry-leading cost discipline. Net margin 19.5% vs. industry 11.3% (+73% premium). ROE 21.0% vs. industry 10.7% (+96% premium) — nearly double peer capital efficiency. These are genuinely world-class metrics. Financial Health (Score 78/100): FCF $1.436B, cash $1.758B — strong liquidity. D/E 0.50x vs. industry 0.65x — below-average leverage. Balance sheet is above-peer quality. Growth (Score 34/100): Revenue growth 8.1% vs. industry 15.6% (-48%); earnings growth 8.5% vs. industry 23.2% (-63%); forward EPS next year 8.75% vs. industry 19.54% (-55%). Agilent is a structural growth laggard. 5-year EPS CAGR estimate of 10.16% vs. industry 12.98% (-22%). Valuation (Score 20/100): P/E 33.93x vs. industry 37.63x (9.8% discount to peers) — but peers deserve higher P/E given 19.5% vs. 8.75% growth. PEG 3.34x vs. industry 6.26x (47% discount) — the discount is entirely explained by Agilent's inferior growth, not cheapness. Analyst target $174.11 implies 1.0% upside — below any reasonable risk premium. Graham-style intrinsic value at 10.2% EPS growth discounted at 10% implies fair value $100-$115, approximately 33-40% below current price.
News Sentiment
Agilent Technologies is riding a wave of investor enthusiasm — but here's the story behind the headlines. The life sciences instrument maker has been busy rolling out new products and catching analyst attention, with 14 out of 20 Wall Street analysts now recommending investors buy the stock. The company just launched two cutting-edge products: the Gen5 AI Cell Identification Module, an artificial intelligence-powered add-on for its BioTek automated imaging systems that could open new software revenue streams, and TapeStationDx Systems — specialized tools for checking sample quality in cutting-edge DNA sequencing used in clinical labs. These aren't just gadgets; they represent Agilent pushing into higher-margin software and clinical diagnostics markets. Meanwhile, investors are cheering signs that China's lab spending is recovering, with Agilent seeing growth from that key market alongside accelerating replacement cycles as aging lab equipment gets upgraded. Agilent also announced a steady $0.255 per share quarterly dividend — a signal that management is confident in cash flow. The company was upgraded to a Zacks Rank Buy rating, adding to the positive momentum. But here's what everyday investors need to know: despite all the good news, the stock's rapid 12% jump in two weeks has outpaced the actual business improvements, leaving very little room for error at current prices. The good news is real — the price just needs to come back down to Earth before it becomes a great buy.
Risk Assessment
Primary risk: valuation compression. At P/E 33.93x with only 8.75% next-year EPS growth (PEG 3.34x), any growth disappointment, guidance cut, or sector rotation toward higher-growth diagnostic peers could trigger a 15-30% de-rating. Secondary risk: China recovery could stall — while headlines are positive on China demand recovery, any reversal would remove a key near-term catalyst. Mitigation for existing holders: the FCF engine ($1.436B), dividend ($0.255/quarter), and profitability moat provide downside cushion — don't sell a quality compounder. Mitigation for new buyers: wait for entry zone $148-$156. At $152 entry, P/E ≈ 29.9x (more defensible for quality compounder), PEG ≈ 2.95x (still elevated but closer to entry-justified), upside to $174.11 analyst target ≈ 14.5%, risk to $141 stop ≈ 7.2%, risk/reward ≈ 2.0:1 — minimally acceptable for quality name. Technical risk: stock now $16.31 above entry zone upper bound; buying here adds $16+ of dead money before reaching proper risk/reward.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is A a halal stock?
Yes, Agilent Technologies, Inc. (A) is halal-compliant per AAOIFI standards as of the latest quarterly review.
What is Plutrex's AI rating for A?
Agilent Technologies, Inc. (A) has a Plutrex AI rating of 52.0/100 with a Hold consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is A a good investment?
According to Plutrex AI, A has a Hold rating (52.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in A?
US stocks like A can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in A?
Plutrex AI identifies the main risks for A by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.